



Media Contact

Carol Berry

Chief Business Officer, SVP

Caprion

cberry@caprion.com

514.360.3600

Caprion to Present Data on Protein Biomarkers Expressed in Alzheimer's and Schizophrenia Patients at the CNS Diseases World Summit

Montreal, Canada – September 18, 2014—Caprion announced today that it will be discussing data regarding the evaluation and identification of protein biomarkers in Alzheimer's and Schizophrenia patients using its mass spectrometry-based proteomics discovery platform, as well as its targeted multiple reaction monitoring (MRM)-based assay for cerebral spinal fluid (CSF) proteins, CNS ProteoCarta™. A modified version of this assay is being used to study Parkinson's disease related proteins with support from the Michael J. Fox Foundation. Caprion's presentation will be on the final day of The CNS Diseases World Summit 2014, which is being held on September 18-19 in San Francisco, CA.

CNS ProteoCarta™ directly addresses the major challenges of high costs and long timelines associated with biomarker validation in human CSF. Developed in collaboration with the FNIH (Foundation for the National Institutes of Health) Biomarkers Consortium, the CNS ProteoCarta assay allows for simultaneous detection and quantification of 142 specific protein biomarkers associated with Alzheimer's disease and neurodegeneration, utilizing minimal CSF specimen volume. Additionally, because of the assay's antibody-independent technology platform, the biomarker panel is easily customized in size and content for other CNS diseases.

Daniel Chelsky, Ph.D., Chief Scientific Officer at Caprion, commented, "Caprion is very interested in further expanding our efforts in neurodegenerative diseases. We are fortunate for past and present opportunities to help advance therapeutic development for patients suffering from Alzheimer's, Parkinson's, Schizophrenia, Huntington's disease, and Multiple Sclerosis." Dr. Chelsky added, "With significant and continual advancements in our proteomics platform, Caprion has already made important contributions to the discovery, verification and validation of biomarkers and therapeutic targets in CNS and other important therapeutic areas."

Presentation Title:

Evaluating Hundreds of Candidate Protein Biomarkers in CSF without Antibodies, Using Mass Spectrometry

Speaker: Daniel Chelsky, Ph.D., Chief Scientific Officer, Caprion

Time: Friday, September 19th, 11:40 AM

Location: Sheraton Fisherman's Wharf Hotel, 2500 Mason St., San Francisco, CA

About Caprion

Caprion is the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Its immune monitoring business unit, ImmuneCarta[®], offers proprietary multiparametric flow cytometry for functional analyses of innate and adaptive immune responses. Caprion's proteomics business unit, ProteoCarta, offers proprietary gel-free, label-free mass spectrometry (MS) for comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples for the discovery and validation of protein biomarkers. Caprion also leverages ProteoCarta[®] to develop its own in-vitro diagnostic products targeting cancer, metabolic and infectious diseases. With research sites in Montreal, Canada and in Menlo Park, CA, Caprion has been providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 10 years. Caprion, a privately-held company, is majority owned by Chicago Growth Partners. For more information, please visit www.caprion.com.